Qualigen Therapeutics, Inc.
Stock Promoter Performance
Last 3 Stock Promotions By "OTC Stock Review"
|CANB||CAN B CORP.||June 28, 2021||0.450||-2%|
|ALAN||Alanco Technologies, Inc.||June 11, 2021||0.017||-13%|
|QSAM||QSAM Biosciences Inc.||April 21, 2021||0.380||4%|
QLGN Promotional Newsletter
The following is a newsletter released by "OTC Stock Review" promoting Qualigen Therapeutics, Inc.
office 404 856-9157
toll-free 866 692-6847
OTC Stock Review Award Winning Small Cap Stock Picks Since 2004
Qualigens NASDAQ QLGN filed an IND with the FDA yesterday on its lead candidate QN-165, which could be an effective treatment against COVID-19 and its variants. Provided the FDA has no questions on the IND, QN-165, which is a potentially broad antiviral drug candidate, will commence Phase 1bPhase 2 clinical trials in 30 days.
Now is the time to get in QN-165 does not attack the coronavirus, or any other virus, directly. It targets a protein called nucleolin, which viruses use to get access to a cell for that cell to replicate. QN-165 is a piece of synthetic DNA that targets and binds to the nucleolin protein and can go into cells that express too much nucleolin. This is totally different than any other drug. Nucleolin is present in all cells in the body. COVID-19 uses the nucleolin protein to gain access to cells so that they can turn cells into what essentially become factories to produce more viruses. QN-165, by tying up nucleolin, blocks that mechanism and prevents the virus replication process. So, when the virus mutates, it doesnt affect the ability of the drug to treat it because QN-165 targets nucleolin instead of the virus itself. This makes Qualigens mechanism of action immune to viral mutations.
Zack's Research has a long-term price target of $10.00.
Qualigen Therapeutics Plans to Combat COVID-19 Variants
Vaccine development to this point has been extraordinary and the initial COVID-19 vaccines have turned out to be highly effective amid the global pandemic.
As evidence of new variants of the virus increases, the durability and extent of protection provided from vaccines for new variants are uncertain.
The World Health Organization has been clear that since these vaccines elicit a broad immune response involving a range of antibodies and cells, mutations in the virus should not make vaccines completely ineffective.
The genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic.
The WHO that manufacturers and the programs using the vaccines may have to adjust to the evolution of the virus by incorporating more than one strain when in development or may need other changes.
Furthermore, there have been reported cases of adverse events and safety in some cases that may affect certain population segments. Along with vaccines, there is also a great need to treat symptomatic patients with COVID-19.
For this reason, the widespread belief is that the coronavirus will be here for a while.
California-based biotechnology company Qualigen believes its unique approach to creating a therapeutic drug may be an effective treatment against COVID-19 and its variants.
Qualigens Potential Solution
Qualigens lead candidate QN-165 is a potentially broad antiviral drug candidate that aims to commence Phase 1bPhase 2 clinical trials in 30 days for COVID-19.
Whats unique about this drug candidate is that it has a completely different approach to attacking a virus. QN-165 is a piece of synthetic DNA that targets and binds to the nucleolin protein and can go into cells that express too much nucleolin.
QN-165 does not attack the coronavirus directly. It targets a protein called nucleolin, which viruses use to get access to a cell for that cell to replicate.
Nucleolin is present in all cells in the body. COVID-19 uses the nucleolin protein to gain access to cells so that they can turn cells into what essentially become factories to produce more viruses.
QN-165, by tying up nucleolin, blocks that mechanism and prevents the virus replication process. Thus when the virus mutates, it doesnt affect the ability of the drug to treat it because QN-165 targets nucleolin instead of the virus itself. This makes Qualigens mechanism of action immune to viral mutations.
Qualigen's therapeutics pipeline includes anti-viral compounds such as QN-165, cancer drug compounds such as QN-247, and RAS-F, as well as STARS, a DNARNA-based treatment device.
Qualigen Inc., has licensed a drug technology developed at the University of Louisville that uses tiny, DNA-coated gold nanoparticles to target cancer.
The technology, dubbed ALAN Aptamer-Linked Au Nanoparticles, has shown promise as an agent for radio-sensitizing and magnetic resonance imaging MRI contrast, as well as for the treatment of many forms of cancer. Here are some of the benefits of conjugating a GNP Gold NanoParticle to QN-165.
Longer Effect AS1411 on its own is great, but conjugated attached to the gold nanoparticle enhances AS1411s potency by making AS1411 stay in circulation longer. Typically, AS1411 gets excreted from the system fairly quickly it is thought that GNP Gold nanoparticle attached to AS1411modifies its pharmacokinetics, causingAS1411 to not get excreted as quickly.
Imaging enhancement In other applications, the GNP can act of like a visual beacon that helps differentiate malignant vs non-malignant cells. AS1411 is already great for its high specificity for nucleolin. GNP conjugated with AS1411 enhances visualization and identification contrasting techniques when imaging dyes are conjugated to the GNP.
Helps Target Magnify Radiation Therapy kind of a corollary to 2. In the same manner above. AS1411-GNP ALAN Acting as a visual beacon Delta Force troops painting the target on the ground can pinpoint the radiation to precise malignant cell targets while also magnifying the radiation effect.
History of Success
Qualigen has a proven track record in the medical diagnostics space being able to develop, get approval, commercialize and generate revenue.
The FastPack line of FDA-cleared and CE-marked products have been used successfully in diagnostics since 2002. It is estimated that thousands of lives have been saved by Qualigens diagnostics, particularly the PSA test for prostate cancer in men.
The long-standing vision of the company is to bring its novel science beyond diagnosing cancer and other diseases, toward differentiated therapeutics. Much of the companys therapeutics pipeline programs have come through collaborations with major academic institutions such as the University of Louisville'
Qualigen has a pipeline of proprietary drug candidates. Apart from QN-165, the lead drug candidate for COVID-19 and potentially other antiviral indications, the company is also developing QN-247, RAS-F and STARS programs.
QN-247, formerly referred to as , is a drug candidate that will be initially developed for Acute Myeloid Leukemia AML, then possibly expanding to cancers of the brain, kidney and liver, with a platform of applications for imaging, diagnostics and drug delivery.
RAS-F is a small molecule drug candidate that targets the downstream effects of RAS mutations including KRAS. It affects a variety of cancers, including pancreatic, lung and colorectal cancers. The initial indication planned for RAS-F is pancreatic cancer.
is a DNARNA-based treatment device candidate to remove circulating blood of precisely targeted, tumor-produced viral compounds.
Products and Pipeline Includes novel platform technologies to treat multiple cancer types and viral diseases
Resources $24 million in cash as of December 31, 2020 providing runway well into 2022 to hit significant value-driving inflection points starting this year
Team Experienced and growing leadership team with a proven track record in development and commercialization
Partnerships Leveraging prominent investigators at major research institutions to cost-efficiently advance development
Value Extensive global IP portfolio over 100 owned or in-licensed, issued or pending patents and applications
To learn more about Qualigen, visit its website .
Qualigen Therapeutics, Inc.
NASDAQ Symbol QLGN
Market Cap $51 million
Shares Outstanding 28.83 million
Sector Health Care
52 Week HighLow $7.34$1.51
2042 Corte Del Nogal
Carlsbad, CA 92011
Qualigen has been in business 25 years and has sold its FastPack products in the United States and overseas for almost 20 years.
Since inception, sales of FastPack products have exceeded $100 million.
OTC Stock Review is not registered as an Investment Advisor or a BrokerDealer. The information in this newsletter is not an offer to buy or sell securities of the companies profiled. Information is for informative purposes, not intended as advice for investment and is subject to change without notice. OTC Stock Review is been compensated seven thousand five hundred dollars a month and twelve thousand five hundred shares of common stock restricted under Rule 144 to perform investor relations services for Qualigen. Officers and directors of OTC Stock Review may hold a long equity position in QSAM and may from time to time trade in these securities for their own accounts. Information on each company is from public releases and can not be guaranteed by OTC Stock Review. Companies profiled herein may carry a high investment risk readers should carefully review profiled companies thoroughly with their investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled Companies and reflects the opinion of the author. Readers should obtain copies of the profiled Companys periodic reports filed with United States Securities and Exchange Commission, generally available at or .
If you no longer wish to receive these emails, please reply to this message with Unsubscribe in the subject line or simply click on the following link
to forward this email to a friend
OTC Stock Review
235 Peachtree St. NE
Atlanta, Georgia 30303
the marketing policy.
Get Every Penny Stock Alert!
OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!
OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.
The information on this page is not a recommendation to buy or sell securities.